NEO(NeoGenomics, Inc.) · 财务报表

NEO(NeoGenomics, Inc.) 的财务报表:医疗保健,诊断与研究。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$484.33M$509.73M$591.64M$660.57M$727.33M
毛利润$187.06M$187.90M$244.60M$290.10M$314.29M
营业利润−$118.75M−$157.62M−$107.74M−$92.11M−$115.88M
净利润−$8.35M−$144.25M−$87.97M−$78.73M−$108.03M
经营现金流−$26.72M−$65.99M−$1.95M$7.02M$5.23M
自由现金流−$90.86M−$96.88M−$30.70M−$34.04M−$21.78M
摊薄每股收益—————

NeoGenomics, Inc. NEO